Investigation of p16 protein expression and its association with histopathologic parameters in breast cancer

Document Type : Original article

Authors

1 Mahzad Women’s Hospital Urmia Medical Sciences University (UMSU), Urmia, Iran

2 Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran

3 Department of Pathology, Urmia University of Medical Sciences, Urmia, Iran

4 Immune Cell Therapy, Stem Cell Transplantation Research Center (HİSRC), Urmia Medical University (UMSU), Urmia, Iran

5 Department of Biostatistics and Epidemiology, School of Medicine Urmia University of Medical Sciences, Urmia, Iran

Abstract

We investigated the association between p16 expression and histopathologic parameters including size, neural and vascular invasion, and lymph node involvement in breast cancer. 58 specimens from patients with different grades of breast cancer were included. Hematoxylin and eosin and immunohistochemistry staining for p16 was performed. 5 patients (8.6%) had grade I, 23 (39.7%) had grade II, and 30 (51.7%) had grade III breast cancer. Assessment of the tumor size showed that 5 (8.6%) tumors had a size of ≤2cm, 29 (50%) were between 2-5 cm and 24 (41.4%) had a size of ≥5cm. Moreover, 45 (77.6%) of the included patients had axillary lymph node involvement. Investigation of association between p16 positivity with pathological parameters in three groups with positivity to p16 (1-25%, 26-75%, >75%) showed that there was no association between p16 positivity and other parameters including histologic score (p=0.44), tumor size (p=0.77), neural invasion (p=0.79), perivascular invasion (p=0.98) and the number of involved LNs (p=0.49). From the group including eight patients with >75% p16 positivity, seven (87.5%) were found with neural invasion and two (25%) with perivascular invasion. P16 positivity was not associated with size, neural and vascular invasion, and LN involvement in breast cancer.

Keywords

References

  1. Taghavi A, Fazeli Z, Vahedi M, Baghestani AR, Pourhoseingholi A, Barzegar F, Pourhoseingholi MA. Increased trend of breast cancer mortality in Iran.  Asian Pac J Cancer Prev 2012;13.367-370.
  2. Rezaianzadeh A, Jalali M, Maghsoudi A, Mokhtari AM., Azgomi SH, Dehghani SL. The overall 5-year survival rate of breast cancer among Iranian women: A systematic review and meta-analysis of published studies. Breast Dis 2017;37:63-68.
  3. Boustan A, Mosaffa F, Jahangiri R, Heidarian-Miri H, Dahmardeh-Ghalehno A, Jamialahmadi K. Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer. Mol Biol Res Commun 2021;10:109-119.
  4. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta 2015;1856:73-85.
  5. Haghnavaz N, Asghari F, Elieh Ali Komi D, Shanehbandi D, Baradaran B, Kazemi T. HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines. Artif Cells Nanomed Biotechnol 2018;46:518-523.
  6. Li J, Chen Z, Su K, Zeng J. Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol 2015;8:8500-8505.
  7. Dumitrescu RG. Interplay between genetic and epigenetic changes in breast cancer subtypes. Methods Mol Biol 2018;1856:19-34.
  8. Radisky DC, Santisteban M, Berman H, Gauthier ML, Frost MH, Reynolds CA, Vierkant RA, Pankratz VS., Visscher DW, Tlsty T, Hartmann LC. p16INK4aexpression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila) 2011;4:1953-1960.
  9. Azechi H, Nishida N, Fukuda Y, Nishimura T, Minata M, Katsuma H, Kuno M, Ito T, Komeda T, Kita R, Takahashi R, Nakao K. Disruption of the p16/Cyclin D1/Retinoblastoma protein pathway in the majority of human hepatocellular carcinomas.  Oncology 2011;60:346-354. 
  10. Tanaka H, Fujii Y, Hirabayashi H, Miyoshi S, Sakaguchi M, Yoon HE, Matsuda H. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer 1998;79:111-115.
  11. Ding Y, Le XP, Zhang QX, Du P. Methylation and mutation analysis of p16gene in gastric cancer. World J Gastroenterol 2003;9:423-426.
  12. Wang L, Zhan X, Shen X, Li M, Yang J, Yu W, Chen H, Jin B, Mao Z. P16 promotes the growth and mobility potential of breast cancer both in vitro and in vivo: the key role of the activation of IL-6/JAK2/STAT3 signaling. Mol Cell Biochem 2018;446:137-148.
  13. Feriancová M, Walter I, Singer CF, Gazdarica J,  Pohlodek  Expression of COX-2, p16, and Ki67 in the range from normal breast tissue to breast cancer. Neoplasma 2021;68:342-351.
  14. Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, Glass A, Zehnbauer BA, Lister K, Parwaresch R. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index
  15. Mod Pathol 2005;18:1067-1078.
  16. Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Löning T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 2001;67:61-70.
  17. Hashmi AA, Naz S, Hashmi SK, Hussain ZF, Irfan M, Khan EY, Faridi N, Khan A, Edhi MM. Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer. BMC Clin Pathol 2018;18:9.
  18. Golmohammadi R, Elyasi H. Relationship between P16 expression and breast cancer using histology and immunohistochemistry. J Mazandaran University Med Sci 2017;27:181-186.
  19. Zhao LH, Liu HG. Immunohistochemical detection and clinicopathological significance of JARID1B/KDM5B and P16 expression in invasive ductal carcinoma of the breast. Genet Mol Res 2015;14:5417-5426.
  20. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012;130:1715-1725.

Files

Share

How to cite

Statistics